Rahmath Meeral P, Doraikannan Srisakthi, Indiran Meignana Arumugham
Department of Public Health Dentistry, Saveetha Dental College & Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, No. 162, Poonamallee High Road, Chennai 600077, India.
Saudi Dent J. 2024 Apr;36(4):521-527. doi: 10.1016/j.sdentj.2024.01.014. Epub 2024 Feb 6.
To assess the remineralizing efficiency of caesin phosphopepdide amorphous calcium phosphate (CPP-ACP) versus topical fluorides on early enamel lesions in vivo.
PubMed, Web of Science, Scopus, EBSCO were searched based on the PICOS criteria up to December 2022 with English language restriction. All relevant studies were subjected to two separate reviews before being included at the title, abstract, and full text levels.
41 studies were reviewed and 11 selected for inclusion in the final sample for the review. All were randomized clinical trials with the follow-up period of the studies ranging from 3 to 12 months. Out of the 11 studies, only two are with low risk of bias on assessment with Cochrane risk of bias assessment tool, while the other nine articles were with the moderate and high risk of bias.
Conflicting evidence exists on the clinical efficacy of CPP-ACP compared to the various fluoride forms tested, and no adverse effect associated with CPP-ACP use was discovered in comparison to fluorides that had certain detrimental health impacts. Although, the review results in favor of both fluorides and CPP-ACP with similar clinical efficiency, when ill effects are considered the CPP-ACP can be a choice of remineralizing early enamel lesions. However, before concrete suggestions can be given, high-quality, well-designed clinical research in this area are still necessary.
A considerable remineralizing impact has been shown in both in vitro and in vivo experiments, making CPP-ACP/CPP-ACPF a more promising remineralizing agent than fluorides. Therefore, this can be applied clinically to early enamel carious lesion.
评估酪蛋白磷酸肽无定形磷酸钙(CPP-ACP)与局部用氟化物对体内早期釉质病变的再矿化效果。
根据PICOS标准,检索截至2022年12月的PubMed、科学网、Scopus、EBSCO,限定语言为英文。所有相关研究在标题、摘要和全文层面纳入前均经过两轮独立评审。
共评审41项研究,11项被选入最终样本进行综述。所有研究均为随机临床试验,随访期为3至12个月。在这11项研究中,使用Cochrane偏倚风险评估工具评估时,只有两项研究的偏倚风险较低,其他九篇文章存在中度和高度偏倚风险。
与测试的各种氟化物形式相比,CPP-ACP的临床疗效存在相互矛盾的证据,与有一定健康危害的氟化物相比,未发现使用CPP-ACP有不良反应。虽然综述结果表明氟化物和CPP-ACP的临床效果相似,但考虑到不良影响,CPP-ACP可作为再矿化早期釉质病变的一种选择。然而,在给出具体建议之前,该领域仍需要高质量、精心设计的临床研究。
体外和体内实验均显示出显著的再矿化作用,使CPP-ACP/CPP-ACPF成为比氟化物更有前景的再矿化剂。因此,可临床应用于早期釉质龋损。